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Introduction
Implantation of a left ventricular assist device (LVAD) as 
a bridge to recovery or transplantation is a widely 
accepted treatment modality. However, in patients with 
cardiac arrest or severe hemodynamic instability and 
multi-organ failure, the outcome is poor1. Extracorporeal 
life support (ECLS) is a well-established technology that 
provides cardiorespiratory support to stabilize severely 
compromised patients, but is only designed for short-
term use2. More than a decade ago, it was shown that an 
LVAD implantation after ECLS placement is possible and 
does not yield inferior results3.
Cardiopulmonary bypass (CPB) is routinely 
required for implantation of VADs. However, CPB is 
associated with adverse effects, including activation of 
the systemic inflammatory response syndrome (SIRS), 
which can result in bleeding, arrhythmias, thromboem-
bolism, neurological disorders, and organ dysfunction4. 
LVAD implantation without CPB has been advocated 
for small axial pumps, as well as for paracorporeal 
devices, but did not get wide-spread acceptance as 
hemodynamic instability may occur and visual inspec-
tion of the left-ventricular cavity is not possible during 
implantation5,6.
In this report, we describe our first use of a percutane-
ous ECLS system as a bridge and assistance to LVAD 
implantation in a patient with severe refractory cardio-
genic shock, to reduce the negative effects associated 
with conventional CPB systems.
Case Report
A 51-year-old man (body surface area: 2.17 m2) was 
referred to our institution with cardiogenic shock due to 
end-stage dilated cardiomyopathy. Despite inotropic sup-
port, the cardiac index still remained at 1.5 L/min/m2. 
Additionally, he presented with orthopnea, somnolence, 
and renal and liver failure.
During ECLS implantation, the patient was not intu-
bated. The left femoral artery (17-Fr) and the right femo-
ral vein (23-Fr) were cannulated under local anesthesia 
using the Seldinger technique and the ECLS system, 
Cardiohelp, (Maquet CP, Hirrlingen, Germany) was 
 connected to create a pump flow of 2.5-3.5 L/min. The 
Cardiohelp system consists of a polymethylpentene diffu-
sion membrane oxygenator and a centrifugal pump, with 
a performance of up to 7 L/min. As the whole system has a 
biocompatible BIOLINE coating, a pronounced systemic 
anticoagulation is unnecessary (partial thromboplastin 
time (PTT) 50–60 sec). Thereafter, the patient recovered 
Successful use of a percutaneous miniaturized 
extracorporeal life support system as a  
bridge and assistance to left ventricular assist 
device implantation in a patient with  
severe refractory cardiogenic shock
A Haneya, A Philipp, T Puehler, D Camboni, M Hilker, 
SW Hirt and  C Schmid
Abstract
We present a 51-year-old man with cardiogenic shock in whom a percutaneous extracorporeal life support system 
(ECLS) was inserted to restore cardiopulmonary stability. After successful stabilization, a left ventricular assist device was 
implanted, using the ECLS without switching to a conventional cardiopulmonary bypass system to reduce its side effects.
Keywords
circulatory assist devices; LVAD; ECLS; ECMO; cardiogenic shock
Department of Cardiothoracic Surgery, University Medical Center 
Regensburg, Regensburg, Germany
Corresponding author:
Assad Haneya MD, 
University Medical Center Regensburg 
Department of Cardiothoracic Surgery 
Franz-Josef-Strauss-Allee 11 
D-93053 Regensburg, Germany
Email: assadhaneya@web.de
419887 PRF27110.1177/0267659111419887Haneya A et al.Perfusion
 at Universitatsbibliothek on August 24, 2016prf.sagepub.comDownloaded from 
Haneya A et al. 19
and shock enzymes normalized. On ECLS, the patient 
received only 1 unit of packed red blood cells (PRBC).
After 7 days of mechanical support, a pulsatile para-
corporeal LVAD (80 mL pump chamber, Berlin Heart 
Excor, Berlin, Germany) was implanted between the left 
ventricular apex and ascending aorta. To reduce the neg-
ative effects associated with conventional CPB, the LVAD 
was implanted with the heart beating, using the ECLS as 
a heart-lung machine. Accordingly, full systemic hep-
arinization was not required; an activated clotting time 
(ACT) between 200 and 250 sec was deemed sufficient. 
The ECLS flow was increased to 4.5 L/min. The apex was 
exposed, using pericardial sutures and lap pads. After 
placement of multiple buttressed sutures at the cannula-
tion site, ventricular fibrillation was induced. An apical 
access to the left ventricle was created, and the apex 
 cannula was inserted, fixed, and de-aired without any 
significant blood loss. The heart was immediately defi-
brillated thereafter. Then, an Excor arterial cannula was 
anastomosed to the ascending aorta with continuous 4-0 
Prolene. Both cannulae were connected to the Excor 
pump. After the ventricle was de-aired, the LVAD pump 
was started and the ECLS was weaned. The ECLS system 
was removed and, after hemostasis, the chest was closed. 
Removal of the ECLS cannulae was simple with manual 
compression of the groin.
Intraoperatively, the patient received 1 unit of PRBC 
and 3 units of fresh frozen plasma because of blood loss 
during cannulation of the apex. Total chest tube output 
at 24 hours was 900 mL. Postoperatively, the patient 
remained hemodynamically stable without inotropic or 
antiarrhythmic medication, and was extubated 14 hours 
later. After 12 hours without bleeding, we started antico-
agulation with heparin (PTT 50-60 sec). Long-term 
anticoagulation consisted of coumarin, together with a 
platelet aggregation inhibitor at a low dosage.
Intensified physiotherapy helped to transfer the 
patient to the step-down unit 9 days later. As native car-
diac function continued to be very poor, the patient is 
listed for heart transplantation.
Discussion
The combination of ECLS and LVAD offers many advan-
tages to the physician. Patients with cardiogenic shock 
can be stabilized by percutaneous implantation of an 
ECLS. This is a simple and quick procedure which allows 
selection of suitable candidates for LVAD placement 
without wasting large amounts of money. Patients 
recover within days and can even be extubated while 
being on cardiorespiratory support. If weaning from 
ECLS is impossible and the patient is eligible for LVAD 
placement, the latter usually follows within 2 to 5 days. 
The intention is a bridge to recovery or a bridge to 
transplantation. Previous studies have reported the 
successful use of a combined ECLS and LVAD approach 
to cardiac salvage for circulatory collapse3,7.
The LVAD implantation using percutaneous minia-
turized ECLS without switching to a conventional CPB 
system is a novel concept. The basic idea is to reduce the 
side effects associated with conventional cardiopulmo-
nary bypass. The concept also saves additional vascular 
cannulation and full systemic heparinization, and offers 
less artificial surface and less priming volume. Thus, at 
least theoretically, the systemic inflammatory response 
syndrome should be reduced. The only disadvantage is 
that visual inspection of the left-ventricular cavity is 
impossible. In our case, the LVAD implantation and the 
perioperative anticogulation management were rather 
simple. Cannulation for LVAD was performed with the 
aid of the ECLS with the heart beating. A careful implant 
technique avoided a significant blood loss from spilling. 
No air embolism or thromboembolism occurred.
In conclusion, our experience suggests that LVAD 
implantation using percutaneous ECLS support without 
switching to conventional CPB is a safe alternative in the 
bridge to bridge concept. This novel approach should be 
useful in selected patients, especially, high-risk patients 
with cardiogenic shock who would benefit from the 
avoidance of the adverse sequels associated with CPB.
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